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Abstract Five hereditary sodium channelopathies of skeletal
muscle have been identified. Prominent symptoms are either
myotonia or weakness caused by an increase or decrease of
muscle fiber excitability. The voltage-gated sodium channel
NaV1.4, initiator of the muscle action potential, is mutated in
all five disorders. Pathogenetically, both loss and gain of
function mutations have been described, the latter being the
more frequent mechanism and involving not just the ion-
conducting pore, but aberrant pores as well. The type of
channel malfunction is decisive for therapy which consists
either of exerting a direct effect on the sodium channel, i.e.,
by blocking the pore, or of restoring skeletal muscle
membrane potential to reduce the fraction of inactivated
channels.
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Introduction
Membrane excitability, which is critical for function of
skeletal muscle, is regulated by ion channels. It is therefore
not surprising that voltage-gated ion channels are involved
in the pathogenesis of diseases of these tissues. Early
research on muscle tissue of patients with hereditary
episodic weakness demonstrated the underlying defect to
be a persistent inward sodium current which depolarized
the membrane causing inexcitability and weakness [28].
Cloning and analysis of the gene encoding the voltage-
gated sodium channel of skeletal muscle confirmed the
electrophysiological results and revealed the first mutations
associated with impaired ion channel function that were
responsible for the skeletal muscle sodium channel disorder
hyperkalemic periodic paralysis [11, 40]. In the 1990s, the
term ion channelopathies was coined and defined for
disorders that are caused by malfunction or altered
regulation of ion channel proteins. Therefore, they may be
either hereditary (for example by mutations in ion channel
genes) or acquired (for example by autoantibodies). Since
then, over 50 channelopathies in human beings have been
described, 12 of which affect skeletal muscle. Of these, five
are caused by mutations in its voltage-gated sodium
channel, NaV1.4: potassium-aggravated myotonia (PAM),
paramyotonia congenita (PMC), hyperkalemic periodic
paralysis (HyperPP), hypokalemic periodic paralysis
(HypoPP), and a form of congenital myasthenic syndrome
(CMS).
This review focuses on the recurrent mutation patterns,
functional consequences, and possible interpretations of the
findings of these diseases. Clinical symptoms are briefly
described and therapeutic options are discussed since many
drugs exist that modulate cell excitability and particularly
sodium channel function. A brief overview of muscle
physiology is provided to outline the significance of the
channels for muscle function.
The resting membrane potential
In skeletal muscle, the resting membrane potential, here
denoted potential 1 (P1), is strongly dependent on inwardly
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increase their conductance with hyperpolarization. There
are two factors which can decrease Kir2.1 conductance:
membrane depolarization and drop of serum potassium,
[K
+]o. Problems for muscle function may arise especially
when both factors change. Even though the Nernst equation
predicts hyperpolarization when [K
+]o is reduced, the
hypokalemia-induced Kir2.1 conductance reduction may
lead to depolarization if [K
+]o is less than 1.5 mM [54].
This phenomenon is called paradoxical depolarization. The
two conditions may form a vicious cycle in which Kir2.1
conductance further decreases with increasing depolarization.
Then, the resting potential becomes instable and drops to the
next stable state, denoted potential 2 (P2), at which other
outward potassium currents activate and counterbalance the
depolarization. Therefore, muscle fibers show a bimodal
distribution of membrane potentials especially at low [K
+]o
[44]. While P1 follows the predictions of the Goldman-
Hodgkin-Katz equation (−83 mVat 4 mM K
+ and −99 mVat
1m MK
+), P2 is about −60 mV and largely independent of
extracellular potassium. The fraction of depolarized fibers
increases when extracellular potassium is only slightly or
moderately lowered [23].
The action potential
The condition for initiating an action potential is that the
net membrane current be inward, in the direction that
results in sufficient depolarization for activation of sodium
channels. The potential at which this condition is reached is
termed the “threshold potential” and is, under normal
conditions, always exceeded by the endplate potential.
The upstroke of the action potential is mediated by opening
of voltage-gated sodium channels that conduct a fast
sodium inward current along both the electrical and
concentration gradient. Due to the resulting high conduc-
tance of the membrane for sodium ions, the membrane
suddenly depolarizes from the resting value of −84 mV to
approximately +25 mV. Immediate repolarization of the
membrane to the highly negative resting value is made
possible by an intrinsic fast inactivation of sodium
channels. Repolarization is driven by the opening of
delayed rectifier potassium channels. Specifically in skele-
tal muscle, repolarization is additionally enforced by a
high-chloride conductance that also buffers the resting
membrane potential. This allows the muscle fibers to
repolarize within about 5 ms despite the large membrane
capacitance resulting from the T-tubular system. After an
action potential, the membrane is inexcitable for a short
period of time, the so-called refractory period, determined
by the kinetics of recovery from inactivation of sodium
channels.
The sodium channel complex
The α-subunit, NaV1.4 consists of 1,836 amino acid
residues [61] and is encoded by the SCN4A gene on
chromosome 17q23.1–25.3. It can be functionally expressed
whereby co-expression of the β1 subunit will modify
kinetics and voltage dependence of channel gating [18].
The tetrameric structure of the α-subunit consists of four
domains (DI–DIV) of six transmembrane helical segments
(S1–S6; Fig. 1). Four voltage sensors, each made of helices
S1–S4, surround the pore domain and control its gates. The
exact mechanisms of voltage sensing and the following
conformational changes leading to channel opening are still
unclear and under intensive investigations [3, 50].
Sodium channel activation results from depolarization-
induced reorientation of the highly charged S4 segments,
which leads to a conformational change of the protein
resulting in the opening of the ion-conducting pore. While
an immediate hyperpolarization closes the channel by
deactivation, an ongoing depolarization will close the
channel by inactivation. Inactivation of sodium channels
may occur by one of several kinetically distinct processes
referred to as fast, intermediate, and slow inactivation, with
time constants in the order of milliseconds, tens to hundreds
of milliseconds, and seconds to minutes, respectively.
Fast inactivation, which is an important factor in shaping
action potentials, occurs during the first milliseconds after
membrane depolarization. Fast inactivation is believed to
function in a so-called hinged-lid mechanism: a hydropho-
bic particle is occluding the channel’s conducting pore from
the intracellular side of the membrane. Fast inactivation
depends on a conserved hydrophobic cluster of three amino
acids IFM (isoleucine, phenylalanine, methionine) in the
DIII–DIV cytoplasmic linker [55, 64]. Residues in the S4–
S5 loops of DIII and DIV are thought to influence
hydrophobic interactions of the IFM motif with its receptor
leading to channel inactivation [38]. Recent studies showed
that the C terminus plays an important role, in stabilizing
the inactivated state [14, 65]. Inactivated channels do not
immediately pass back into to the resting state after
hyperpolarization, but require a certain amount of recovery
time to do so.
Slow inactivation occurs after depolarization for seconds
or minutes. Slow inactivation plays an important role by
contributing to the regulation of resting sodium channel
availability [43] and by aiding in slow activity-dependent
changes in excitability such as spike frequency adaption or
burst termination [58]. The molecular mechanism of the
slow-inactivation process is still poorly understood. How-
ever, slow inactivation is distinct from fast inactivation
because mutations that eliminate fast inactivation do not
abolish slow inactivation [9, 56]. As large rearrangements
are involved in slow inactivation several channel regions
240 Pflugers Arch - Eur J Physiol (2010) 460:239–248determine slow inactivation: pore regions, the voltage
sensors, and segments S5 and S6.
Channelopathies
Five sodium channelopathies of skeletal muscle have been
identified to date. All of them follow an autosomal
dominant mode of transmission. Four of the disorders
which are caused by similar NaV1.4 gain-of-function effects
have distinct clinical features and therapies which may even
be contrary despite common pathogenesis. Although the α
subunit’s function is modulated by the β1 subunit, all
mutations that cause a muscle disease are situated in
NaV1.4. The only known β1 mutation causes generalized
epilepsy with febrile seizures plus for which skeletal muscle
dysfunction has not been described [60].
The cardinal symptoms of the diseases are myotonia and
muscle weakness. Myotonic muscle stiffness is the result of
uncontrolled repetitive muscle fiber discharges, which is
based on increased membrane excitability most likely
originating from the T-tubular system. Muscle weakness
or even paralysis is usually caused by fiber inexcitability or,
as in congenital myasthenic syndrome, by a reduced safety
factor of synaptic transmission at the motor endplate.
Potassium-aggravated myotonia
PAM includes myotonia fluctuans, moderate myotonia,
myotonia permanens, acetazolamide-responsive myotonia,
and painful myotonia, i.e., a spectrum of diseases with
overlapping clinical features which have in common that, in
contrast to the allelic disorders paramyotonia congenita,
hyperkalemic periodic paralysis and hypokalemic periodic
paralysis, no weakness occurs [25, 37, 48]. The prevalence
of PAM is estimated at ∼1:400,000 [29].
At first glance, myotonia fluctuans and moderate PAM
are clinically very similar to the better known Thomsen
myotonia, which is caused by mutations in the main
chloride channel of skeletal muscle, ClC-1 [24]. However,
in addition to stiffness of Thomsen patients which is most
expressed during the first contractions after rest and
improves with further contractions (warm-up phenomenon),
PAM patients become stiff 10 to 30 min after strenuous
work. This delayed and sometimes painful stiffness may
hinder the patient’s movements for several hours. It should
not be confused with paradoxical myotonia, i.e., myotonia
worsening with repeated contractions. Usually, most limb
muscles show the warm-up phenomenon. Furthermore,
potassium and other depolarizing agents (and sometimes
cold) aggravate the myotonia, a reaction that is not
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Fig. 1 α-Subunit of the voltage-gated sodium channel of skeletal
muscle, NaV1.4. The alpha-subunit is composed of four highly
homologous domains (DI–DIV) each consisting of six transmembrane
segments (S1–S6). When inserted in membrane, the four domains of the
protein fold to generate a central pore whereby the S5–S6 loops form
the ion-selective pore. The S4 segments contain positively charged
residues conferring voltage dependence to the protein. Domains are
connected by intracellular loops; one of them, the DIII−DIV linker,
contains the inactivation particle of the channel. The sketch gives an
overview of locations of known NaV1.4 mutations
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potassium was responsible for origination of the term
potassium-aggravated myotonia [17, 34].
Most PAM mutations are situated in the N terminus of
loops that connect domains (Fig. 1)—particularly in the
inactivation gate. Three of the mutations in this gate
(G1306A/V/E) affect different amino acid substitutions for
one of a pair of glycines proposed to act as the “hinge” for
the inactivation gate. The more the substituting amino acid
differs from the physiological G1306, the more severe are
the clinical symptoms. Alanine, with a short side-chain,
results in a benign, often “subclinical” form of myotonia
(myotonia fluctuans), valine, having a side-chain of inter-
mediate size, causes moderate myotonia, and glutamic acid,
an amino acid with a long side-chain, causes permanent
myotonia, the most severe form of the disease [31, 33].
According to disease severity, G1306A shows the
mildest, G1306V the moderate (Fig. 2), and G1306E the
most severe slowing of fast inactivation and acceleration of
recovery from inactivation in the heterologous expression
system [31, 33]. In addition to fast channel inactivation,
also activation and deactivation are affected whereas slow
inactivation is normal. Variation of extracellular potassium
has no direct effect on the mutant channels. However,
measurements on excised fibers from patients showed that
potassium exerts its effect via physiological depolarization,
an effect which cannot be observed under experimental
voltage-clamp conditions. The increased sodium inward
current generates after-depolarizations across the T-tubular
membrane which re-approaches activation threshold and,
triggers repetitive action potentials [1]. Normally, influen-
ces from the activation threshold, resting membrane
potential, and the size of after-depolarizations are tuned to
avoid re-activations. In myotonia, usually more than one of
these factors is changed, i.e., the activation threshold of the
action potential is shifted or its amplitude and time-course
are changed which might amplify after-depolarizations. An
increase of potassium concentration in the T-tubules is
pivotal, since this would depolarize the T-tubular membrane
and thereby facilitate re-excitation [1]. With every addi-
tional action potential, T-tubular potassium concentration
rises further. Finally, T-tubular potassium accumulation will
terminate the bursts by depolarization and subsequent
inactivation of NaV1.4.
Paramyotonia congenita—stiffness followed by flaccid
weakness
The cardinal symptom is cold-induced muscle stiffness that
increases with continued activity (paradoxical myotonia). In
the cold (or even in a cool wind), the face may appear
mask-like, and the eyes cannot be opened for several
seconds or minutes. On intensive cooling, the stiffness
a
b
Fig. 2 Currents through WT
and mutant sodium channels. a
Whole-cell sodium current
traces of WT and PAM mutant
(G1306V) sodium channels. b
Single-channel recordings for
WT and mutant sodium chan-
nels. Sodium currents were eli-
cited by step depolarizations
from a holding potential of
−120 mV in 10 mV steps to
+30 mV. Re-openings were
more frequent for mutant chan-
nels, thereby leading to a small
persistent current. Modified after
Mitrovic et al. [34]
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Families with R1448 substitutions also have episodes of
generalized periodic paralysis [29]. Such attacks occur
spontaneously and can be triggered by rest or potassium.
They are of short duration (an hour or less) in comparison to
the cold-induced weakness which usually lasts for several
hoursevenwhenthemusclesareimmediatelyre-warmedafter
ashortboutofexposuretocold.Underwarmconditions,most
patients have no complaints because impaired muscle
relaxation improves at higher temperatures. The prevalence
is about 1:200,000 [29].
Most of the 16 PMC mutations are situated in protein parts
relevant for channel inactivation: in the inactivation particle
IFM itself like F1311V (unpublished observation) and nearby
like T1313M/A [4, 66], in the outermost arginine of the
voltage sensor of DIV (R1448H/C/S/P/L), in intracellular
S4–S5 loops of DIII or DIV (e.g., F1473S) [10], or in the C
terminus [65]. Functional expression revealed slowed fast
inactivation and accelerated recovery from the inactivated
state [6, 15]. These gain of function changes lead to action
potential facilitation as already explained. A recent study
pointed out, that resurgent currents, i.e., currents conducted
by sodium channels which re-open during the repolarization,
may contribute to the pathogenesis of PMC [19]. In
neurons, these unusual sodium currents are proposed to
result from a putative intracellular blocking factor that
binds to open channels preventing classical inactivation,
but unbinds during repolarization at potentials at which
channels normally remain inactivated. The blocking
factor has been hypothesized to be a beta subunit, for
example beta-4, which is present in skeletal muscle and
could contribute to the hyperexcitability of PMC.
Except for one controversially discussed study [36], all
studies carried out so far showed minor differences in
temperature sensitivity between WT and PC mutations [7,
10, 32]. This leads to the conclusion that the effect of
temperature on excitability in PC is simply a result of the
normalslowingofchannel kineticswithcoolingandisnot the
consequence of any alteration in the temperature sensitivity of
sodium channel properties. Therefore, temperature sensitivity
inPCmightbeexplainedasathresholdphenomenon[10, 32].
A recent study of Webb and Cannon [62]s u g g e s t st h a t
temperature dependency of slow inactivation may contribute
to the phenotype.
Hyperkalemic periodic paralysis
HyperPP patients present with increased serum potassium
during episodes of weakness. They may not have any
interictal symptoms and are therefore often thought to
exhibit a conversion reaction, and the subsequent omission
of adequate therapy may cause them to suffer needlessly.
Weakness is triggered by a variety of circumstances
including rest after exercise, potassium-rich food, cold
environment, emotional stress, fasting, and pregnancy.
Between episodes, the disease is often associated with
myotonia, which is mild and does not impede voluntary
movements but may exacerbate at the beginning of the
weakness spell.
Mutations causing HyperPP, slow fast inactivation to an
extent, that channels fail to inactivate completely even after
long-lasting depolarizations. As a result, there is persistent
sodium inward current as shown in excised fibers obtained
from patients [28] and as intracellular sodium accumulation
in vivo [63]. The persistent sodium conductance leads to
membrane depolarization and drives an outward flux of
potassium into the extracellular space. Fiber depolarization,
persistent sodium current, and hyperkalemia form a vicious
cycle which spreads out and affects the surrounding muscle
tissue. The resulting hyperkalemia can be so severe that
cardiac complications arise.
Most of the HyperPP Nav1.4 mutations are situated at
inner parts of the transmembrane segments and in the
intracellular loop connecting transmembrane segments S5
and S6 of DII. They affect structures that form the three-
dimensional docking site for the fast inactivation particle.
Any malformation may reduce the affinity between the
“latch bar and the catch”. The mutant channels avoid the
inactivated state and, in contrast to normal sodium
channels, re-open or flicker between the inactivated and
the open state [16, 59]. In HyperPP, slow inactivation of the
mutant channels is incomplete, especially for mutations
situated at the S5/S6 loop.
During a paralytic episode, death may occur due to
respiratory insufficiency. Independently of the severity and
frequency of the paralytic episodes, many patients develop
a chronic progressive myopathy in the forties, an age at
which the attacks of weakness decrease. Patients without
interictal myotonia are much more prone to develop the
progressive myopathy and permanent weakness than
individuals with myotonia. This becomes especially obvi-
ous in individuals with the most common T704M mutation
which is not associated with EMG myotonia in half of the
patients, and about half of the T704M patients develop
permanent myopathy. The second most frequent mutation,
M1592V, always is associated with EMG myotonia and
permanent myopathy has never been reported.
Hypokalemic periodic paralysis
HypoPP differs from the hyperkalemic form in the sense
that a spontaneous attack is associated with hypokalemia,
potassium is a remedy, whereas carbohydrate- and sodium-
rich food triggers an attack. In general, the attacks last
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weakest during the second half of the night and in the
morning, and become stronger as the day goes by.
HypoPP is caused by mutations in two voltage-gated
cation channels in skeletal muscle Cav1.1 (HypoPP-1) and
Nav1.4 (HypoPP-2) [12, 21, 22]. Almost all mutations
neutralize a positively charged amino acid in one of the
outermost arginines or lysines of a voltage sensor. The
Nav1.4 mutations are situated in the voltage sensors of DI,
DII, and DIII. The electrophysiological characterization of
the gating defects induced by these mutations revealed a
loss of channel function, which does not explain the
phenotype [27]. By expressing HypoPP mutations in
Xenopus oocytes, Sokolov et al. [45] and Cannon et al.
[47] discovered a cation leak with the typical characteristics
found for the ω-current in Shaker K
+-channels [49]. The
ω-current, so called to differentiate it from the (α-)current
through the ion-conducting pore, is a hyperpolarization-
activated current of monovalent cations that is thought to
flow through the S4 gating pore (Fig. 3). The ω-current
counteracts the Kir2.1 current and therefore depolarizes and
destabilizes the resting membrane potential so that the
fraction of fibers in P2 is increased [20]. This has been
observed in preparations obtained from patients [23]. In
vivo, the muscles from these patients exhibited an intracel-
lular sodium accumulation and edema.
As muscle fibers with a severe voltage sensor mutation
are depolarized not only during hypokalemia but also at
potassium levels in the normal range, this membrane leak
might not only explain episodes of weakness, but interictal
(permanent) weakness as well. The permanent weakness
associated with a fatty replacement myopathy is very
frequently found in patients harboring DIV mutations in
the calcium channel, i.e., Cav1.1 R1239H [23].
Normokalemic periodic paralysis
The term normokalemic periodic paralysis (NormoPP) was
originally given to a variant described in the 1960s. The
disorder resembled hyperkalemic PP in many aspects;
the only real differences were the lack of increase in the
concentration ofserum potassium evenduringserious attacks,
and the lack of a beneficial effect of glucose administration
[29]. The existence of NormoPP as a nosologic entity was
questioned because of the potassium sensitivity of the
patients and the identification of the most frequent hyper-
kalemic PP mutations T704M or M1592V in such families
including the original family.
Recently, a potassium-sensitive type of periodic paraly-
sis with normokalemia and episodes of weakness reminis-
cent of those in both hyperkalemic (initiation of an attack
by potassium) and hypokalamic forms (duration of attacks)
was reported [57]. This phenotype, also named NormoPP, is
caused by SCN4A mutations at deeper locations of the
voltage sensor of domain II at codon 675 (Fig. 1).
Functionally, R675 mutations generate an ω-current with a
reversed voltage dependence compared to mutations causing
HypoPP-2 [46], since this site is exposed to the extracellular
space at stronger depolarizations. Future studies will show
whether NormoPP is a separate clinical entity. The diag-
nostics are as described for the two more common forms of
the disease. The prophylaxis consists of avoidance of
hyperkalemia and the administration of acetazolamide.
Pathophysiological basics of weakness
Primary myogenic paralysis is based on muscle inexcit-
ability which is caused by depolarization beyond −60 mV.
This may be due to the aforementioned paradoxical
depolarization described for [K
+]o reduction. The paralytic
state corresponds to P2. At this potential, Nav1.4 is subject
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Fig. 3 Leak currents. a A replacement of the outermost arginine (red)
by a smaller amino acid (blue), e.g., glycine, opens a conductive
pathway at hyperpolarized potentials, resulting in an inward cation
current (blue). At depolarized potentials at which the S4 segment
moves outward, the conductive pathway is closed and the cation
current ceases. b Schematic of cation currents through sodium
channels carrying charge-neutralizing substitutions in S4 voltage
sensors. Note the large inward current in the hyperpolarized potential
range corresponding to the resting state of the leaky S4 voltage sensor
244 Pflugers Arch - Eur J Physiol (2010) 460:239–248to closed-state inactivation. Transition jumps between the
two states (P1 and P2) occur when any trigger drives the
system closer to or shifts a limit point, so that the current
state becomes instable (Fig. 4a). The limit points of both
states (LP1 and LP2) have different locations in the state
space. Therefore, hysteresis is a typical feature of such a
system. If [K
+]o is considered as a control parameter as in
Fig. 4a, it reveals its important role in driving the system to
its limits.
Normal muscle does not become paralytic because the
limit points are located at very low potassium concen-
trations that do not occur physiologically. The location of
LP1 has been measured in diaphragm of rat muscle
(Fig. 4b, c)[ 23]. Results from a single fiber of mouse
lumbricalis muscle have been published by Geukes-Foppen
et al. [13] and suggest a hysteresis of about 1 mM. If the
limit points were shifted to higher potassium concentra-
tions, transitions between the states would be possible
under physiological conditions and result in periodic
paralysis. Hypokalemic periodic paralysis is caused by
such a shift. The shift is induced by a small depolarizing
leak current (ω-current) and by a reduction of resting
potassium conductance [42, 52]. As an in vitro model, the
pharmacological induction of a small depolarizing leak
current by amphotericin B has been successfully applied
(Fig. 4b, c).
Paralytic attacks are triggered by certain endocrine or
physical challenges. The triggers seem to have in common
that they affect [K
+]o by either changing internal potassium
balance or shifting the limit points. Typical triggers that
reduce [K
+]o and therefore provoke attacks in hypokalemic
periodic paralysis are: insulin, catecholamines (β2-agonists),
glucocorticoids, and rest after exercise. Triggers for hyper-
kalemic periodic paralysis, where an instability of P1
emerges at increasing [K
+]o values [5]a r e :p o t a s s i u m - r i c h
meals and exercise. The fact that a limit point or threshold
has to be reached to provoke a change in stability might
explain the periodicity of the paralytic attacks. Hysteresis is
reflected in the clinical fact, that, for recovery from paralysis,
a
b
c
0.0
0.1
0.2
0.3
0.4
0.5
0.6
p
r
o
b
a
b
i
l
i
t
y
 
d
e
n
s
i
t
y
/
m
M
-
1
extracellular K
+ 
concentration/mM
0
0.2
0.4
0.6
0.8
f
r
a
c
t
i
o
n
 
o
f
 
p
o
l
a
r
i
z
e
d
 
f
i
b
e
r
s
extracellular K
+ 
concentration/mM
0246
246
0246
-100
-80
-60 LP2
LP1
m
e
m
b
r
a
n
e
 
p
o
t
e
n
t
i
a
l
/
m
V
extracellular K
+ concentration/mM
Fig. 4 Bistable membrane potentials and pathogenesis of hypokalemic
periodic paralysis. a Bifurcation diagram of a mathematical model of
skeletal muscle with the extracellular K
+ concentration as the control
parameter. Beginning at high K
+ concentrations, a reduction reveals an
instability of the resting potential at the limit point, LP1 (closed circles),
from which a sudden transition to about −60 mVoccurs. Increasing the
K
+ concentration from low values takes the muscle fiber to another limit
point, LP2 (open circles), where the system jumps back into a state with
normal membrane potentials. Control (red line), additional small (5 µS/
cm
2) depolarizing current and insulin-induced reduction of Kir
conductance as in HypoPP (blue line), regions of instability (dashed
line). b Fraction of rat diaphragm muscle fibers with normal membrane
potentials after the reduction of [K
+]o to different values, without (red)
and with (blue) amphotericin B, a Na
+ and K
+ ionophore. Curves
represent fits of a log-normal cumulative distribution function (modified
from [23]). c Probability density functions computed with fit parameters
from (b). These functions give the probability of a transition from the
normal to the depolarized state for responding fibers at different [K
+]o.
LP1 may be defined as the mode or the median of the curves.
Amphotericin B causes an increment of mode, median, and SD by
1 mM, 1.5 mM, and 1.2 mM, respectively. Therefore, in the presence of
a small depolarizing leak current, LP1 is shifted to the right and a
paradoxical depolarization is more likely to occur even at normal [K
+]o
b
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+]o has to change more than it did when it provoked
weakness.
Muscle membrane potentials provide an explanation for
the weakness observed directly following cold-induced
paramyotonia as well. During cooling to 27°C in vitro,
excised PMC muscle fibers slowly depolarized from
−85 mV to about −45 mV whereas normal muscle fibers
depolarized by not more than 5 mV. The depolarization was
associated with a long-lasting burst of action potentials
which stop as soon as the membrane potential approximates
values of −45 to −50 mV [30, 32]. At this voltage, also the
mutant sodium channels are inactivated and therefore the
muscle fibers become inexcitable and paralyzed.
Congenital myasthenic syndrome
CMS is a heterogeneous group of inherited disorders with
defective transmission of neuromuscular excitation resulting
inmusclefatigue[8]. They result from defects in presynaptic,
synaptic, and postsynaptic proteins. Of the postsynaptic
CMS that are usually caused by mutations in the nicotinic
acetylcholine receptor, one form has been identified as
sodium channelopathy. Two alterations in Nav1.4 have been
identified, S246L in the S4–S5 cytoplasmic linker in DI, and
V1442E in the S3–S4 extracellular linker in DIV [53]. While
S246L is likely a benign polymorphism, V1442E revealed a
marked enhancement of fast inactivation even at hyper-
polarized potentials, and enhanced use-dependent inactiva-
tion on high-frequency stimulation. The reduced availability
of sodium channels decreases the safety factor of synaptic
transmission.
Medication of skeletal muscle sodium channelopathies
The aim of drug therapy in myotonia is to reduce the
involuntaryactionpotential burstswithoutblockingvoluntary
high-frequency muscle stimulation. This is a delicate balance
between drug-induced reduction of voluntary tetanic muscle
strength and too little antimyotonic effects. Fortunately, local
anesthetics and anti-arrhythmic drugs of class IB effectively
relieve stiffness in PAM and prevent muscle stiffness and
weakness occurring in PMC with cooling [2, 41]. These
agents stabilize the inactivated channel by a hyperpolarizing
shift in steady-state inactivation and by slowing the recovery
from inactivation. Agents such as mexiletine, flecainide, and
other lidocaine analogs, prevent repetitive firing of action
potentials due to their "use dependence", a dependence of the
depth of block on the frequency of action potentials. The
degree of use dependence varies with the structure (charge
and hydrophobicity) of the drug. Beyond this “unspecific”
antimyotonic effect, the agents seem to be more effective on
certain mutant sodium channels than on wild-type channels
[35]. Unfortunately, the spontaneous and potassium-
induced attacks of weakness typical for hyperkalemic
P Pa n da l s oo c c u r r i n gi ns o m eP M Cp a t i e n t sa r en o t
improved by mexiletine [39]. However, diuretics such
as hydrochlorothiazide and acetazolamide can decrease
frequency and severity of paralytic episodes, probably by
lowering serum potassium and perhaps by shifting the pH
to lower values.
In HypoPP, acute weakness spells can be treated by
potassium and be prevented by certain carbonic anhydrase
inhibitors, aldosterone antagonists, and potassium-sparing
diuretics. Serum potassium levels in the high normal range
help reduce the paradoxical membrane depolarization and
therefore shift the resting potential from P2 to P1 values.
Acetazolamide also lowers intracellular sodium accumula-
tion in these patients [23] addressing both pathogenetic
factors in HypoPP: depolarization and sodium accumula-
tion. The repolarizing effect of acetazolamide may be
explained at least partially by opening of big conductance
potassium channels [51].
Perspectives
As ion channels constitute one of the only protein families
that allow functional examination on the molecular level,
expression studies of putative mutations have become
standard in supporting the disease-causing nature of
mutations. While this is quite helpful, one must not over-
interpret functional changes that a mutation produces
because these changes may not necessarily indicate a
disease-causing mutation but a functional polymorphism
instead [26]. Therefore, while functional studies are
essential, they do not alleviate from the need for careful
observation of clinical phenotype, response to therapy, and
genetic screening of large and adequately matched control
populations, for interpretation of pathogenesis of ion
channel disorders.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which per-
mits any noncommercial use, distribution, and reproduction in any
medium, provided the original author(s) and source are credited.
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